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Abstract
Aims/hypothesis Sphingolipids play important roles in beta cell physiology, by regulating proinsulin folding and insulin secre-
tion and in controlling apoptosis, as studied in animal models and cell cultures. Here we investigate whether sphingolipid
metabolism may contribute to the pathogenesis of human type 1 diabetes and whether increasing the levels of the sphingolipid
sulfatide would prevent models of diabetes in NOD mice.
Methods We examined the amount and distribution of sulfatide in human pancreatic islets by immunohistochemistry, immuno-
fluorescence and electron microscopy. Transcriptional analysis was used to evaluate expression of sphingolipid-related genes in
isolated human islets. Genome-wide association studies (GWAS) and a T cell proliferation assay were used to identify type 1
diabetes related polymorphisms and test how these affect cellular islet autoimmunity. Finally, we treated NOD mice with
fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes
development.
Results We found reduced amounts of sulfatide, 23% of the levels in control participants, in pancreatic islets of individuals with newly
diagnosed type 1 diabetes, which were associated with reduced expression of enzymes involved in sphingolipid metabolism. Next, we
discovered eight gene polymorphisms (ORMDL3, SPHK2,B4GALNT1, SLC1A5,GALC,PPARD,PPARG andB4GALT1) involved in
sphingolipid metabolism that contribute to the genetic predisposition to type 1 diabetes. These gene polymorphisms correlated with the
degree of cellular islet autoimmunity in a cohort of individuals with type 1 diabetes. Finally, using fenofibrate, which activates sulfatide
biosynthesis, we completely prevented diabetes in NOD mice and even reversed the disease in half of otherwise diabetic animals.
Conclusions/interpretation These results indicate that islet sphingolipid metabolism is abnormal in type 1 diabetes and suggest
that modulation may represent a novel therapeutic approach.
Data availability The RNA expression data is available online at https://www.dropbox.com/s/93mk5tzl5fdyo6b/Abnormal%
20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%2C%20RNA%20expression.xlsx?dl=0. A list of
SNPs identified is available at https://www.dropbox.com/s/yfojma9xanpp2ju/Abnormal%20islet%20sphingolipid%
20metabolism%20in%20type%201%20diabetes%20SNP.xlsx?dl=0.
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Tcells . Type 1 diabetes
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Introduction
Type 1 diabetes is characterised as an autoimmune disease in
which autoreactive T cells infiltrate the pancreatic islets and
destroy the insulin producing beta cells [1]. However, the po-
tential importance of beta cell dysfunction, rather than complete
beta cell loss, in the pathogenesis of type 1 diabetes has recently
been emphasised by the demonstration that a majority of indi-
viduals with diabetes retain a significant proportion of insulin-
positive islets at disease onset [2–4]. In support of this, islets
isolated from pancreatic biopsies taken from individuals with
type 1 diabetes partly regained their ability to secrete insulin in
response to glucose when cultured in a non-diabetogenic envi-
ronment in vitro [5], while the majority of individuals with type
1 diabetes regained insulin production immediately upon treat-
ment with autologous system cell therapy [6]. Potential key
players in this beta cell dysfunction are sphingolipids, a diverse
group of lipids found in all cellular membranes, having diverse
roles as both structural components and signalling molecules
[7–9]. Sphingolipids are known to have important roles in beta
cell biology [10, 11] and have been linked to the development
of diabetes-associated pathologies [12]. One especially impor-
tant sphingolipid is sulfatide (3-O-sulfogalactosylceramide)
which acts as an insulin chaperone, preserves insulin crystals
and regulates insulin secretion by influencing the gating of
ATP-sensitive potassium channels [13, 14]. However, most
studies regarding the role of sphingolipid metabolism in beta
cells have been conducted in animal models and cell cultures.
Here, we tested the hypothesis that sphingolipid metabolism is
contributing to the pathogenesis of human type 1 diabetes from
several perspectives. Using blood and tissue samples from
pancreas biopsies from newly diagnosed individuals with type
1 diabetes, we found evidence suggesting that sphingolipid
metabolism plays a role in type 1 diabetes pathology. Based
on this we tested whether increasing pancreatic sulfatide levels
could prevent and reverse experimental autoimmune diabetes in
NOD mice.
Methods
Human tissue Pancreatic tissue was collected in the Diabetes
Virus Detection (DiViD) studies as described previously [15].
In short, individuals with diabetes between 25 and 35 years of
age had a surgical minimal pancreatic tail resection obtained by
laparoscopy 3 to 9 weeks after the onset of type 1 diabetes. The
DiViD study was approved by The Norwegian Government’s
Regional Ethics Committee (reference 2009/1907). UK tissue
samples from the Exeter Archival Diabetes Biobank had all been
collected prior to the study and were made available with ethical
approval from the West of Scotland Research Ethics Service
(reference 15/WS/0258). The tissue from donors with type 2
diabetes and non-diabetic control donors, used for RNA analy-
ses, was acquired from the network of Pancreatic Organ Donors
(nPOD; with approval by the University of Tennessee Health
Science Center (UTHSC) local Institutional Review Board [ref-
erence 10-00848-XM]). The pancreatic tissue from participants
without diabetes used for sulfatide staining was acquired from
Rigshospitalet, Copenhagen, Denmark, as completely
anonymised (unknown age and sex) healthy tissue removed
from pancreas samples after resection for surgical treatment of
pancreatic cancer and was used in accordance with the rules by
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Region Hovedstaden Committee on Health Research Ethics.
Human islets for electronmicroscopywere obtained as described
previously [16]. Peripheral blood samples were collected from
individuals with type 1 diabetes, aged between 1 and 39 years
after informed consent was obtained as approved by theMedical
Ethical Committee of Leiden University Medical Center (refer-
ence CME05/68C). For all participant information see electronic
supplementary material (ESM) Table 1.
Immunohistochemistry Immunohistochemistry on
neighbouring pancreatic sections from the DiViD study and
control participants was performed using anti-sulfatide anti-
body Sulph I (a gift from P. Fredman, Gothenburg University,
Sweden [17]; diluted 1:150) or guinea pig anti-insulin (Dako,
Ely, UK; diluted 1:700). Visualisation was performed using
ultraView Universal DAB Detection Kit (Roche, Basel,
Switzerland). The light microscope BX51 (Olympus
America, Melville, NY, USA) was used to analyse the stained
specimens. For the UK sections, immunohistochemistry was
visualised using Dako REAL EnVision Detection System,
Peroxidase/DAB+ (Dako) and light microscope Nikon 50i
Eclipse (Nikon, Kingston-upon-Thames, UK). The relative
sulfatide level in pancreatic islets was compared with control
participants without diabetes. Staining in all control partici-
pants was set to one (100%) and the staining intensity in
minimum 30 islets from each donor was evaluated.
Immunofluorescence staining Pancreatic sections were stained
with an anti-sulfatide antibody (diluted 1:150) and a secondary
Alexa Fluor 488 antibody (Life Technologies, Paisley, UK;
diluted 1:400). Pancreatic sections were co-stained with an
anti-glucagon antibody raised in rabbit (Abcam, Cambridge,
UK; diluted 1:4000) and with guinea pig anti-insulin (Dako;
diluted 1:700) plus relevant secondary antibodies labelled with
Alexa Fluor 647 and Alexa Fluor 568 (Life Technologies; (di-
luted 1:400). Images were captured under fluorescence illumi-
nation using a Leica AF6000 microscope (Leica, Milton
Keynes, UK). Leica application suite X software (Lecia) was
used to remove background staining and crop images.
Electron microscopy Isolated pancreatic human islets were
incubated overnight at 4°C with Sulph I (diluted 1:1000)
and washed in 1% PBS-BSA. Next the islets were incubated
overnight at 4°C with 1 nm gold labelled goat anti-mouse IgG
(Aurion, Wageningen, the Netherlands; diluted as 1:300). The
islets were postfixed in 2% glutaraldehyde for 2 h, before
silver enhancement using AURION R-GENT SE-EM
(Aurion). The islets were then washed in distilled water before
osmication in 1%OsO4 diluted in 0.1 mol/l cacodylate buffer.
After washing in 0.1 mol/l cacodylate buffer, the specimens
were dehydrated in alcohol and embedded in Epon Resin 812
before ultra-sections were examined in a Philips 208 electron
microscope (Philips, Eindhoven, the Netherlands).
RNA analyses Frozen tissue (optimal cutting temperature
[OCT]) sections were obtained from the nPOD [18] and
DiViD tissue collections. Tissue slides were fixed and laser-
capture of islets conducted as previously described [19]. All
islets in two to five sections of tissue from each donor were
captured and pooled and RNA extracted using the Arcturus
PicoPure RNA Isolation Kit (Applied Biosystems, Grand
Island, NY, USA). Quality and quantity of RNA was deter-
mined on a Bioanalyzer 2100 instrument (Agilent
Technologies, Santa Clara, CA, USA). Samples with suffi-
cient quantity and quality of RNAwere then subjected to gene
expression analysis using Affymetrix expression arrays
(GeneChip Human Gene 2.0 ST) and scaled normalised gene
expression values produced as previously described [20]. The
normalised expression data for 70 genes of interest were then
subjected to analysis as described below.
GWAS analyses The 70 genes examined at the RNA level were
also evaluated using GWAS to look for a genetic association
with type 1 diabetes. Immunochip SNPs for type 1 diabetes
were retrieved from Onengut-Gumuscu et al 2015 [21]. A cut-
off p value <0.02 was used to retrieve nominally significant
SNPs. SNPs within (±100 kb flanking regions) of the examined
genes were identified for further analysis. We used
Encyclopedia of DNA Elements (ENCODE) regulatory fea-
tures (ChIP-Seq peaks, DNase I hypersensitivity peaks,
DNase I footprints) from University of California Santa Cruz
(UCSC) genome browser [22] (http://genome.ucsc.edu/) and
RegulomeDB [23] to identify potential regulatory SNPs likely
to affect the expression of the associated gene. We also
integrated data from multiple expression quantitative trait loci
(eQTL) studies [24–26] to identify SNPs associatedwith chang-
es in expression (cis-eQTLs) of their associated gene. The cis-
eQTL effects were calculated using linear regression models in
the selected tissues (whole blood, fibroblast and lymphoblastoid
cell lines) using a ciswindow of ±1MB around the transcription
start site at significance level of p < 0.05 [24–26]. SNPs map-
ping to HLA regions were excluded from the analysis.
Blood donors Peripheral blood was collected from 71 indi-
viduals with type 1 diabetes. Peripheral blood mononucle-
ar cells (PBMCs) were isolated by Ficoll density gradient
centrifugation and resuspended in Iscove’s Modified
Dulbecco’s Media (IMDM) (Life Technologies, Paisley,
UK.) containing 10% heat-inactivated human serum (HS;
Sanquin, the Netherlands). PBMCs were subsequently test-
ed for the presence of autoreactive T cells using a T cell
proliferation assay.
SNP genotyping and genetic risk score DNA was isolated
from PBMCs of individuals with type 1 diabetes using the
DNeasy Blood & Tissue Kit (Qiagen Benelux, Venlo, the
Netherlands). DNA concentration was determined by
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NanoDrop and samples were concentrated at 50 ng/μl. SNP
genotyping was performed on the Infinium ImmunoArray-24
v2 BeadChip Kit (Illumina, Eindhoven, the Netherlands) ac-
cording to the manufacturer’s protocol.
To test the cumulative effect of identified SNPs on islet
autoimmunity, we computed a genetic risk score (GRS) in
all individuals with type 1 diabetes. GRS is the sum of the
number of risk alleles (0, 1 or 2) multiplied by the natural log
of the OR for each SNP, divided by the total number of SNPs.
SNPs were also individually analysed. The SNPs selected for
the study were based on the SNP with the lowest p value and
the highest OR was examined for each of the genes identified
in the GWAS analysis.
T cell proliferation assay AT cell proliferation assay was per-
formed on PBMCs freshly isolated from individuals with type
1 diabetes to investigate autoimmunity towards GAD65,
preproinsulin (PPI), islet antigen-2 (IA-2) and insulin-
defective ribosomal product (INS-DRiP). Human recombi-
nant proteins GAD65, PPI, IA-2 and INS-DRiP were pro-
duced as previously described [27, 28]. PBMCs were seeded
(150,000/well) in round-bottomed 96-well microculture plates
(Greiner, Nürtingen, Germany) and cultured for 5 days in
IMDM containing 10% HS at 37°C in 5% CO2, in a humid-
ified atmosphere. Cells were cultured in triplicates in medium
alone, with 10 μg/ml recombinant GAD65, PPI, IA-2 or INS-
DRiP or with recombinant IL-2 (35 units/mL; Genzyme,
Cambridge, MA, USA) as positive control. After 16 h of cul-
ture, 50 μl RPMI medium 1640 (Dutch modification; Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) containing
18500 Bq [3H]thymidine (DuPont, Boston, MA, USA) was
added per well. After the cells were harvested on filters with
an automated harvester, proliferation was determined by the
measurement of 3H-thymidine incorporation in an automatic
liquid scintillation counter. All results are calculated as mean
counts per min (CPM) in the presence of antigen and com-
pared with medium alone. Stimulation index (SI) = mean
CPMANTIGEN/mean CPMMEDIUM. An SI ≥3 is considered
positive. In three participants, INS-DRiP was not measured.
Animals and diabetes monitoring Female NOD mice
(Taconic Biosciences, Hudson, NY, USA) were kept in a spe-
cific pathogen-free (SPF) animal facility (temperature 22°C,
12 h light cycle, air change 16 times per h and humidity 55 ±
10%). Animal experiments were approved by the Animal
Experiments Inspectorate, Ministry of Food, Agriculture and
Fisheries of Denmark (reference 2012-15-2934-00086) and
experiments performed according to international guidelines
for the care and use of laboratory animals. The mice had free
access to drinking water and standard Altromin 1320 diet
(Altromin, Lage, Germany) with or without 0.01% fenofibrate
(Sigma, St Louis, MO, USA). The mice were inspected week-
ly for diabetes from an age of 84 days using FreeStyle Lite
(Abbott, Chicago, IL, USA) glucose monitoring. Diabetes di-
agnosis was based on two blood glucose measurements >12
mmol/l with an interval of 2 days, all measurements were
made between 09:00 and 13:00 hours. The date of the first
blood glucose measurement >12 mmol/l was used as diabetes
onset date. Mice were killed by cervical dislocation at onset of
diabetes or at the age of 217 days. Distribution of animals into
groups and diabetes monitoring was not performed blinded. In
the reversal studies, fenofibrate treatment was immediately
commenced at the onset of diabetes and continued for 3weeks.
No inclusion or exclusion criteria were used.
Insulitis and sulfatide scoring of NOD mice Insulitis score was
calculated from six mice in each group, at 13 weeks old.
Pancreases were removed, fixed in 10% neutral buffered for-
malin overnight, embedded in paraffin and sectioned in 5 μm
sections that were subsequently stained in haematoxylin and
eosin. The sections were evaluated randomly and blinded
using an Olympus BX53 microscope (Olympus America).
Twenty-five islets from each mouse were scored according
to the following scale: 0, no infiltration; 1, intact islets but
with few mononuclear cells surrounding the islets; 2, peri-
insulitis; 3, islet infiltration below 50% and 4, islet infiltration
above 50%. Neighbouring slides were stained for sulfatide
and scanned using NanoZoomer-XR (Hamamatsu,
Hamamatsu City, Japan). For each mouse one slide was
scored and the staining intensity was evaluated using a scale
from 0 to 4 with 0 denoting no sulfatide and 4 denoting inten-
sity as seen in neurons. The scoring was performed blinded.
Statistics The statistical analysis was performed using
GraphPad Prism version 6.01 (GraphPad, La Jolla, CA,
USA) and data is shown as mean ± SEM unless otherwise
noted. The cumulative diabetes incidence was assessed using
logrank Mantel–Cox. Correlation between insulitis and
sulfatide was performed with a linear regression. For compar-
isons between groups a two-tailed unpaired Student’s t test or
a one-way ANOVA with Tukey’s multiple comparisons test.
The percentage of participants with a positive T cell response
was evaluated using a χ2 test and two-proportions Z test. Data
were natural log-transformed before analysis if not normally
distributed. A p value of less than 0.05 was considered signif-
icant. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Results
Sulfatide is reduced in human pancreatic islets at the onset of
type 1 diabetes To study sulfatide levels in human islets at the
onset of type 1 diabetes, a sulfatide specific antibody was
employed to compare islet immunostaining. Pancreas biopsies
from individuals with newly diagnosed type 1 diabetes includ-
ed in the DiViD study, had reduced sulfatide staining as
Diabetologia (2018) 61:1650–1661 1653
compared with control participants without diabetes (Fig. 1a).
Of the islets in the six DiViD individuals with diabetes, 63%
were sulfatide positive and had a relative sulfatide staining
intensity of 23% SEM ±6% (p < 0.0001) compared with the
control group. This loss of sulfatide was observed in all six
individuals studied and was confirmed in a separate cohort of
individuals with type 1 diabetes from the Exeter Archival
Diabetes Biobank (Fig. 1b).
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Fig. 2 Altered expression of enzymes involved in sphingolipid metabo-
lism at the onset of type 1 diabetes. RNAwas isolated from laser-dissect-
ed islets and analysed bymicroarray. The individuals with type 1 diabetes
are from the DiViD study. The mean difference in per cent ± SEM is
shown. Solid line at zero represents control average. Control (n=18);
white squares, type 1 diabetes (n=5); black triangles, type 2 diabetes
(n=8). *p<0.05; **p<0.01; ****p<0.0001. One-way ANOVA with
Tukey’s multiple comparisons test
Insulin
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T1D
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Fig. 1 Sulfatide is present in beta cells and is lost from insulin-positive
islets at the onset of type 1 diabetes. (a) Immunohistochemical staining of
insulin and sulfatide from a control participant without diabetes and a
patient with new-onset type 1 diabetes from DiViD. The pictures represent
a standard islet as found in all six DiViD cases. Immunohistochemistry
shows pronounced insulin staining and no sulfatide in individuals with type
1 diabetes. Scale bar, 50 μm. (b) Immunohistochemical staining of
sulfatide of three healthy control participants and three newly diagnosed
individuals with type 1 diabetes from the UK. Scale bar, 50 μm. (c)
Immunofluorescent staining of a pancreas without diabetes showing that
sulfatide is expressed in beta cells. Scale bar, 30 μm. (d) Electron micros-
copy on an isolated pancreatic human islet stained for sulfatide. Sulfatide is
localised to insulin granules in beta cells. T1D, type 1 diabetes
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Analysis of multiple islets from four pancreases revealed
that sulfatide was found only in beta cells, but absent in alpha
cells (Fig. 1c), which was confirmed by electron microscopy
(Fig. 1d). Sulfatide was occasionally detectable in islet cells
negatively for both insulin and glucagon (ESM Fig. 1).
Reduced expression of enzymes involved in sphingolipid me-
tabolism in human pancreatic islets at the onset of type 1
diabetes A microarray analysis was performed to examine
the expression of enzymes involved in sphingolipidmetabolism
in human islets. RNAwas isolated from the islets of individuals
with new onset type 1 diabetes (DiViD), individuals with type 2
diabetes and control participants without diabetes. RNA levels
of 70 genes involved in sphingolipid metabolism were evaluat-
ed and 13 genes were found to have significantly altered ex-
pression at the onset of type 1 diabetes compared with control
participants (Fig. 2). SPTLC2 (which encodes serine
palmitoyltransferase long chain base subunit 2), a subunit of
serine palmitoyltransferase (SPT) which catalyses the first step
in sphingolipid synthesis [29], was reduced (by 31%, p = 0.04).
Similarly, the expression of the SPT inhibitor ORMDL2
(encoding ORMDL sphingolipid biosynthesis regulator 2)
[ 3 0 ] a nd a c t i v a t o r SPTSSA ( e n c od i n g s e r i n e
palmitoyltransferase small subunit A) [31] were also reduced
53%, p < 0.0001; 56%, p < 0.0001, respectively. Expression of
enzymes involved in the generation and modification of cer-
amide were also reduced, including ceramide synthase 2
(CERS2) which was decreased (26%, p = 0.004). Expression
of ceramide galactosyltransferase (CGT, also known as
UGT8 ) , ce ramide kinase (CERK ) and ceramide
glucosyltransferase (UGCG) were similarly diminished; by
30%, p = 0.005; 39%, p = 0.003 and 37%, p = 0.03, respective-
ly. We also found a reduced expression of lysosomal
arylsulfatase K (ARSK; 41%, p = 0.004). Our results indicate
an altered distribution of complex glycosphingolipids in type
1 d i ab e t e s , w i t h i n c r e a s ed exp r e s s i on o f t h e
galactosyltransferase, B3GALT5 (which encodes β-1,3-
galactosyltransferase 5) (35%, p = 0.002), whereas B3GALT4
(encodingβ-1,3-galactosyltransferase 4) andB4GALT1 (β-1,4-
galactosyltransferase 1) were downregulated (by 39%, p = 0.01
and 34%, p = 0.02, respectively). Finally, we observed a re-
duced expression of two amino acid transporters; SLC1A4
(encoding solute carrier family 1 member 4) (33%, p = 0.009)
and SLC7A10 (solute carrier family 7 member 10) (32%, p =
0.01) which facilitate the uptake of the sphingolipid precursor
serine into cells [32]. None of the examined genes had altered
expression in type 2 diabetes compared with control
participants.
SNPs in promoter regions of enzymes involved in
sphingolipid metabolism associate with the development of
type 1 diabetes Next, we tested whether SNPs in genes in-
volved in sphingolipid metabolism were associated with ge-
netic predisposition to type 1 diabetes. GWAS have identified
around 50 loci that influence the risk of developing type 1
diabetes but the disease-promoting genes at these loci often
remain unknown [33]. We examined regions 100 kb upstream
and downstream of the transcriptional start site of 70 genes
involved in sphingolipid metabolism (Table 1). A p value
<0.02 was selected to identify all SNPs associated with type
1 diabetes, as previously described [34]. SNPs mapping to the
HLA regions were excluded from the analysis. RegulomeDB,
which ranks SNPs based on the likelihood of the SNP
influencing gene expression, was used with a cut-off of ≤3
to prioritise SNPs with a likely regulatory activity [23]. We
identified eight genes with SNPs associated with an increased
risk of type 1 diabetes and a RegulomeDB score ≤3 (Table 1)
and OR up to 1.47. Five genes coding for enzymes involved in
Table 1 Genes related to sphingolipid metabolism are in type 1 diabetes-associated genetic regions
Gene Total type 1 diabetes
SNPs (p<0.02)
SNPs
(RegulomeDB ≤3)
OR
(RegulomeDB ≤3)
p value
(RegulomeDB ≤3)
cis-eQTL p value
(tissue/cell-line)
ORMDL3 155 36 1.20 (rs75290103) 1.20×10−8 (rs12150079) 2.6×10−11 (whole blood)
SPHK2 82 18 1.13 (rs281388) 5.28×10−10 (rs33988101) 0.032 (whole blood);
8.4×10−4 (cells: transformed fibroblasts)
B4GALNT1 54 14 1.47 (rs41292013) 9.43×10−5 (rs775251) –
SLC1A5 50 14 1.16 (rs10412340) 4.72×10−8 (rs402072) 1.4×10−7 (cells: transformed fibroblasts)
GALC 42 3 1.06 (rs17798191) 0.01 (rs10139328) 2.3×10−5 (cells: EBV-transformed lymphocytes);
0.033 (whole blood)
PPARD 27 4 1.13 (rs7744392) 8.74×10−3 (rs7744392) 2.7×10−3 (cells: transformed fibroblasts)
PPARG 4 1 1.17 (rs77040839) 0.018 (rs77040839) –
B4GALT1 1 1 1.12 (rs7019909) 5.57×10−4 (rs7019909) 7.7×10−5 (cells: transformed fibroblasts);
0.008 (cells: EBV-transformed lymphocytes)
Type 1 diabetes-associated SNPs (p < 0.02) were identified in eight genes (±100 kb) involved in sphingolipid metabolism. Genes located in proximity to
HLA regions have been excluded. Genes are ranked according to the total number of type 1 diabetes-associated SNPs. The RegulomeDB score, which
ranks SNPs based on the likelihood of the SNP influencing gene transcription (the lower the more likely), was used with a cut-off ≤3 to prioritise SNPs
with a likely regulatory function. In genes with more than one SNP, the highest OR/lowest p value is mentioned. OR is based on the minor allele for
B4GALNT1, PPARG and SLC1A5 and the major allele for B4GALT1, GALC, ORMDL3, PPARD and SPHK2. The last column reports the cis-eQTL p
value in disease relevant tissues/cell lines for the SNP with the lowest p value
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sphingolipid biosynthesis (ORMDL3 [ORMDL sphingolipid
biosynthesis regulator 3], SPHK2 [sphingosine kinase 2],
B4GALNT1 [β-1,4-N-acetyl-galactosaminyltransferase 1],
GALC [galactosylceramidase] and B4GALT1), two transcrip-
tion factors (peroxisome proliferator-activated receptor
(PPARs) D and G), which regulate the expression of enzymes
in sphingolipid metabolism [35] and the amino acid transport-
er SLC1A5 (solute carrier family 1 member 5), which is in-
volved in the uptake of sphingolipid precursor L-serine
(Table 1). Of these ORMDL3 has been previously described
[36]. Next, we used cis-eQTLs to evaluate the predicted effect
of the SNPs on the expression levels of their associated gene.
We integrated data from pre-calculated cis-eQTLs [24]. For
six genes (ORMDL3, GALC, SPHK2, SLC1A5, PPARD and
B4GALT1) the SNPs with the strongest association with type
1 diabetes (lowest p value) also acted as cis-eQTLs, suggest-
ing that these SNPs regulate the expression of their associated
genes (Table 1).
Increased genetic risk defined by sphingolipid-related SNPs is
associated with reduced proliferation of islet-specific T cells in
individuals with type 1 diabetes We wanted to evaluate
whether the identified SNPs could affect islet autoimmunity.
The most promising SNPs (lowest p value and highest OR for
each gene, as shown in Table 1) were selected and a GRS
based on the number of risk alleles and OR per SNP was
computed. The GRS was correlated to proliferation of T cells
in response to islet autoantigens GAD65, PPI, IA-2 and INS-
DRiP [28] as measured by the SI. A cohort of 71 individuals
with type 1 diabetes were divided between three risk groups:
low genetic risk (GRS = 0.11–0.14, n = 20); intermediate
(GRS = 0.14–0.16, n = 37) and high (GRS > 0.16, n = 14).
When comparing the GRS with the proliferation against all
islet autoantigens (SISUM = SIGAD65 + SIPPI + SIIA-2 + SIINS-
DRiP) we surprisingly found that islet-specific T cells from
intermediate- and high-risk patients proliferated less than
those with a low-risk (p = 0.047 and p = 0.017, respectively;
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Fig. 3 Sphingolipid-related SNPs associate with cellular islet autoimmu-
nity in individuals with type 1 diabetes. Proliferation of Tcells specific for
GAD65, PPI, IA-2 and INS-DRiP in PBMCs freshly isolated from indi-
viduals with type 1 diabetes. Patients were divided into risk groups based
on sphingolipid-related genetic risk: low (GRS=0.11–0.14, n=20); inter-
mediate (GRS=0.14–0.16, n=37) and high (GRS >0.16, n=14). Data were
normalised by natural log-transformation. SI ≥3 is considered positive.
Tukey boxplots are shown. (a) Cumulative proliferation of islet-specific T
cells (SISUM =SIGAD65+SIPPI+SIIA-2+SIINS-DRiP) in patient-risk groups.
(b) Proliferation of T cells in patient-risk groups plotted per islet-
autoantigen. Dashed line indicates SI=3. (c) Percentage of patients within
each risk group with positive Tcell proliferation responses (SI ≥3) plotted
per islet-autoantigen. Light grey bars, low GRS; medium grey bars, in-
termediate GRS; dark grey bars, high GRS. (d, e) Proliferation of PPI-
specific T cells in heterozygous and homozygous carriers of the (d)
rs12150079 or (e) rs33988101 risk allele vs non-carriers of the respective
risk allele. *p<0.05; **p<0.01. One-way ANOVAwith Tukey’s multiple
comparisons, χ2 two-proportions Z test and two-tailed unpaired Student’s
t test
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Fig. 3a). Focusing on individual islet autoantigens, we found
that PPI-specific T cells proliferated less in intermediate- and
high-risk patients compared with those at low-risk (p = 0.007
and p = 0.002, respectively) and IA-2-specific T cells prolifer-
ated less in high-risk patients compared with those at low-risk
(p = 0.018), with a non-significant difference in the interme-
diate group (p = 0.31); there were also non-significant differ-
ences in proliferation for INS-DRiP among both high- and
intermediate risk groups compared with the low-risk group
(p = 0.159 and p = 0.069, respectively), but not for GAD65
(Fig. 3b). Looking at the percentage of patients in each risk
group with positive proliferation responses against individual
islet autoantigens (SI ≥3), we found that fewer patients in the
high-risk group responded to PPI compared with the low-risk
group (p = 0.003; Fig. 3c). Moreover, even though there were
no significant differences in absolute INS-DRiP-specific Tcell
proliferation, the percentage of patients with a positive INS-
DRiP response was significantly lower in the intermediate-
risk group than in the low-risk group (p = 0.034).
Furthermore, we found that heterozygous and homozygous
carriers of the risk alleles rs12150079 (ORMDL3) and
rs33988101 (SPHK2) had lower levels of Tcell autoimmunity
(p = 0.042 and p = 0.017, respectively; Fig. 3d,e).
Increasing sulfatide levels in mice pancreatic islets is associ-
ated with prevention of autoimmune diabetes in NOD mice
Based on these findings, we considered pharmacological up-
regulation of pancreatic sulfatide levels as a possible therapeu-
tic approach in type 1 diabetes. NOD mice were therefore
treated with fenofibrate, which is known to increase sulfatide
levels in several organs [37]. NOD mice, which usually de-
velop insulitis at age 4 weeks [38], were treated with
fenofibrate from an age of 3 weeks till 35 weeks.
Development of diabetes was prevented in the fenofibrate
treated mice (0/15 (0%) vs 11/15 (73%) in the control group
(p < 0.0001; Fig. 4a). Fenofibrate also reduced the degree of
insulitis (p = 0.0006; Fig. 4b,c) and increased the expression
of sulfatide in islets (p = 0.007; Fig. 4d). There was an inverse
correlation between sulfatide and insulitis score (p = 0.0004,
r2 = 0.72; Fig. 4e) in the experimental animals. Fenofibrate
treatment initiated after onset of diabetes reversed diabetes
in 46% (6/13) NOD mice after 3 weeks of treatment.
Discussion
The present study provides human data demonstrating that
sphingolipid metabolism contributes to genetic disease predis-
position and autoimmunity and that the onset of type 1 diabe-
tes is associated with altered sphingolipid metabolism and
reduced expression of sulfatide in pancreatic islets (Fig. 5).
Sulfatide is known to participate in the regulation of first-
phase insulin secretion [13] and it is possible that the observed
loss of pancreatic sulfatide may contribute to the loss of first-
phase insulin secretion seen during the development of type 1
diabetes [39]. We notice a finer granulation in the islets of
individuals with type 1 diabetes; whether this might, in part,
influence the reduced sulfatide-staining that is seen in insulin
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granules, is unknown [14]. Reduced levels of sulfatide might
be explained by reduced enzyme expression as suggested by
the transcriptome analysis, which showed reduced expression
of several enzymes involved in sphingolipid metabolism in
islets from individuals with newly diagnosed type 1 diabetes
(Fig. 5a). The reduced expression of CERS2 is particularly
interesting since this points towards altered hydrocarbon chain
lengths of beta cell sphingolipids in type 1 diabetes, with
lower amounts of long chains [40]. Long chain (C24) sulfatide
is protective against diabetes development in NOD mice [41].
Furthermore, a low-grade enteroviral infection was found in
the beta cells of all DiViD participants [5] and this could be
linked to lower expression of C24 sulfatide which stimulates
the natural killer (NK) T cells that normally eliminate diabe-
togenic viruses [41, 42]. We did not find any changes in the
expression of arylsulfatase A, which degrades sulfatide in the
lysosome [43], suggesting that the reduced amount of
sulfatide did not result from enhanced rates of lipid degrada-
tion. The changed expression of B3GALT5, B3GALT4 and
B4GALT1 suggest that the development of type 1 diabetes is
associated with changes in the composition of islet
glycosphingolipids with increases in the neolacto/lacto series
and decreased levels of gangliosides (ESM Fig. 2). An altered
amount of gangliosides could play a role in type 1 diabetes
aetiology as ganglioside autoantibodies are found at the onset
of disease [44]. Altered levels of ceramide and sphingosine-1-
phosphate could also affect islet function through regulation
of the sphingolipid rheostat [45].
To support these findings, GWAS data were interrogated
and SNPs in the promoter regions of eight genes influencing
sphingolipid levels were identified (Fig. 5b). Among these,
the OR of 1.47 calculated for B4GALNT1 ranks it among the
highest risk genes implicated in the predisposition to type 1
diabetes (ESM Fig. 3). All SNPs identified here correlated
with predisposition to type 1 diabetes but not type 2 diabetes.
It should be noted that the SNPs identified could be inhibitory
or activating and so the overall effect of these SNPs on
sphingolipid composition is difficult to predict.
The most promising SNPs were found to be associated
with lower rates of T cell proliferation when these cells
were presented with beta cell autoantigens (Fig. 5c). This
effect was linked with autoimmunity to PPI and to a less-
er degree IA-2 and INS-DRiP, but not GAD65. A possible
explanation for this seemingly paradoxical finding is that
sulfatide is involved in PPI folding [46] and likely the
formation of INS-DRiP. T cells recognise folded PPI and
so impaired folding due to less sulfatide would lead to a
lower immune response against PPI. A lack of sulfatide
on the other hand would not affect autoimmunity to
GAD65.
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Overview of how sphingolipid metabolism is related to the development
of type 1 diabetes. (a) There is a reduced amount of sulfatide in islets of
individuals with newly diagnosed type 1 diabetes (images taken from Fig.
1b). This is related to altered expression of enzymes involved in the
biosynthesis of sphingolipids in islets. (b) Genetic polymorphisms in
the promoter region of eight genes encoding enzymes involved in
sphingolipid metabolism increases the risk for developing type 1 diabetes.
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proliferation when presented to beta cell autoantigens. (d) Fenofibrate
stimulates sulfatide production in islets of NOD mice. (e) This is associ-
ated with complete protection against diabetes and a lower degree of
insulitis in NOD mice; insulitis image adapted from [50] (original cour-
tesy of A. van Halteren) with permission of Springer Nature
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Fenofibrate has been in use for decades to reduce LDL-
cholesterol, triacylglycerol and cholesterol levels and has
shown beneficial effects on the prevention of diabetic neurop-
athy and retinopathy [47]. Here we demonstrate that NOD
mice were protected from insulitis and diabetes by early ex-
posure to fenofibrate and that this correlated with an increase
in islet sulfatide levels (Fig. 5d,e). The positive effect of
fenofibrate, however, cannot be solely credited to the in-
creased amount of sulfatide as fenofibrate is also likely to
affect other aspects of lipid biology. Previous studies have
otherwise shown that the ceramide synthase inhibitor
FTY720 [48] prevented diabetes development in NOD mice
[49], highlighting the diverse roles of different sphingolipids
in diabetes pathology.
In conclusion, we provide human evidence of an altered
islet sphingolipid metabolism in type 1 diabetes. Increasing
sulfatide levels prevents diabetes in NODmice suggesting that
upregulation of sulfatide biosynthesis may represent a prom-
ising therapeutic route in type 1 diabetes.
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